EBITDA margins improved 1810 bps YoY to 41.7% (I-direct estimates: 38.5%) mainly due to Oseltamivir exclusivity. EBITDA grew 159% to | 241 crore (I-direct estimate: | 215 crore) Adjusted net profit increased 178% YoY to | 177 crore (I-direct...